

Ref. No.: WOCK/SEC/SE/ 2024-25/063

16th October, 2024

National Stock Exchange of India Limited

Listing Department
Exchange Plaza
Bandra Kurla Complex, Bandra (E),
Mumbai - 400 051

NSE Symbol – WOCKPHARMA

Dear Sir/ Madam,

Sub: Reply to your email dated 15th October, 2024 relating to Volume Movement

This is in response to your letter ref. no. NSE/CM/Surveillance/14870 dated 15th October, 2024. We would like to state that, we regularly disseminate all the information that have a bearing on the operation/performance of the company which include all price sensitive information within statutory timelines.

We believe that the sudden increase in volume may be on account of our recent press release submitted on 11th October, 2024 relating to Company's product i.e. novel antibiotic MiqnafTM (Nafithromycin) which received favourable recommendation from Subject Expert Committee of Central Drugs Standard Control Organization (CDSCO) for the Treatment for Community-Acquired Bacterial Pneumonia (CABP).

At this point of time, the Company does not have any specific information/ announcement which have a bearing on the price or volume behaviour of the scrip. Please note that the Company submits the requisite disclosures to the Stock Exchanges and shall continue to do so as part of its obligation under Regulation 30 of the SEBI Listing Regulations or other relevant applicable laws. Kindly take the above information on record.

Thanking you,

For **Wockhardt Limited**

Rashmi Mamtura
Company Secretary